Ventricular Ectopic QRS Interval May Be Useful Post-MI Marker

Share this content:
Ventricular Ectopic QRS Interval May Be Useful Post-MI Marker
Ventricular Ectopic QRS Interval May Be Useful Post-MI Marker

MONDAY, June 6, 2016 (HealthDay News) -- The ventricular ectopic QRS interval (VEQSI) can identify post-myocardial infarction (MI) patients with prior serious ventricular arrhythmia, according to a study published online June 1 in JACC: Clinical Electrophysiology.

Rachel Bastiaenen, Ph.D., from St. George's University Hospitals NHS Foundation Trust in London, and colleagues analyzed 12-lead Holter recordings from 189 patients with previous MI: 38 with prior life threatening events (MI-VT/VF) and 151 without prior significant ventricular arrhythmia (MI-no VT/VF). Results were compared with those from 60 healthy controls. All ventricular ectopic beats (VEB) were reviewed; the duration of the longest VEB was recorded as VEQSI max.

The researchers found that VEQSI max was longer in post-MI patients than healthy controls, and in MI-VT/VF patients with prior life threatening events than in MI-no VT/VF patients without prior life threatening events (both P < 0.001). VEQSI max was established as the strongest independent marker for prior serious ventricular arrhythmia in multivariate analysis. For identifying patients with prior life threatening events, VEQSI max >198 ms had 86 percent sensitivity, 85 percent specificity, 62 percent positive predictive value, and 96 percent negative predictive value (odds ratio, 37.4).

"This may be a useful additional index for risk stratification in ischemic heart disease," the authors write.

One author disclosed financial ties to Boston Scientific and Medtronic; Boston Scientific partially funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days

AAN: New Drug May Help Infants With Spinal Muscular Atrophy

AAN: New Drug May Help Infants With Spinal ...

RG7916 increases survival motor neuron protein level, with 6.5-fold increase noted with highest dose

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small overall effect size for frequent and heavy cannabis use among adolescents, young adults

is free, fast, and customized just for you!

Already a member?

Sign In Now »